Fluorescence molecular tomography: principles and potential for pharmaceutical research.
about
Advances in optical imaging for pharmacological studies.The role of lymphatics in cancer as assessed by near-infrared fluorescence imagingAbsorption reconstruction improves biodistribution assessment of fluorescent nanoprobes using hybrid fluorescence-mediated tomography.Volumetric chemical imaging by stimulated Raman projection microscopy and tomography.Noninvasive depth estimation using tissue optical properties and a dual-wavelength fluorescent molecular probe in vivo.Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancerImpact of Substituents in Tumor Uptake and Fluorescence Imaging Ability of Near-Infrared Cyanine-like DyesNear-infrared fluorescent proteins engineered from bacterial phytochromes.Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review.Fluorescent nanoparticles for the accurate detection of drug delivery.Targeting β-amyloid plaques and oligomers: development of near-IR fluorescence imaging probes.Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical ImagingFluorescence molecular tomography of DiR-labeled mesenchymal stem cell implants for osteochondral defect repair in rabbit knees.Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation.Multimodal molecular 3D imaging for the tumoral volumetric distribution assessment of folate-based biosensors.Evaluation of molecules based on the electron donor-acceptor architecture as near-infrared β-amyloidal-targeting probes.Ultrasmall Superparamagnetic Iron Oxide Nanoparticles with Europium(III) DO3A as a Bimodal Imaging Probe.Performance of optoacoustic and fluorescence imaging in detecting deep-seated fluorescent agents.Image reconstruction in fluorescence molecular tomography with sparsity-initialized maximum-likelihood expectation maximization.Functional probes for cardiovascular molecular imagingSlice-illuminated optical projection tomography
P2860
Q26781583-84470696-3886-4028-AFDF-6D9473B9BA22Q27001155-D4D612A9-24C1-4CDE-8C12-A2F6F64FC145Q30432543-2BA9E1AB-B570-47BE-A951-C291D75FE615Q30847522-D6EE875A-6294-48F9-AE5F-C5750BBD04CEQ33824518-22BD7868-9060-425B-AEF4-7E88EC39F5E9Q34334475-EC2C197F-BBC8-4CFA-9156-DB08E3A234D9Q35673522-63058F36-0965-41EB-9994-791BA0EE2793Q36005927-5E267D4E-AFDB-4CB3-9025-ED3499F67A3FQ38369228-E5C7CE1F-60DC-467D-81F3-48D7E1F1594AQ38570366-EE1FCAEA-91BD-437B-AC0D-E73AEB6DD8A8Q38765176-77D242F4-9929-4643-B3DE-7140407E76BDQ39135714-98CE2EB8-4733-48D8-B9A0-747C72D5BD56Q40688805-A798F88B-31C7-4DEF-A278-182090D658C7Q47245673-C4D55DA3-CDB4-48A4-9717-68946F9E99ABQ47592063-2312ADFB-8005-4E36-9019-52CF8DD34F99Q48585670-F9585BEE-0D3F-42FB-8F6A-DCA05DB222F6Q50259902-96456B9A-DB83-4B0E-B42B-5AE1F23EE2A0Q55141679-891104A7-2ED6-496D-9853-468A74531969Q55427816-5C3CA157-E636-4704-82D7-949400D8B37AQ57300751-4C02427A-1D8A-4161-8E70-CA94E93E7C9BQ59136642-47639DFD-C0C3-424A-8815-9EDCBCADC3BC
P2860
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
@ast
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
@en
type
label
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
@ast
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
@en
prefLabel
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
@ast
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
@en
P2093
P2860
P1433
P1476
Fluorescence molecular tomography: principles and potential for pharmaceutical research.
@en
P2093
Florian Stuker
Jorge Ripoll
Markus Rudin
P2860
P304
P356
10.3390/PHARMACEUTICS3020229
P577
2011-04-26T00:00:00Z